Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4 | Zendy

Stuart M. Sprague | Zendy; Hanna E. Abboud | Zendy; Ping Qiu | Zendy; Matthew Dauphin | Zendy; Pinggao Zhang | Zendy; William F. Finn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4

Author(s) -

Stuart M. Sprague,

Hanna E. Abboud,

Ping Qiu,

Matthew Dauphin,

Pinggao Zhang,

William F. Finn

Publication year - 2008

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02830608

Subject(s) - lanthanum carbonate , hyperphosphatemia , tolerability , medicine , phosphate binder , placebo , population , kidney disease , sevelamer , gastroenterology , urology , adverse effect , pathology , alternative medicine , environmental health

Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research